Myriad Genetics Inc
MYGN· Nasdaq
MYGNMyriad Genetics Inc
Filed Feb 28, 2024 · 10-K · 59 days after period end · 0000899923-24-000018
derived · Computed from the longer spans the company filed.
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020 |
|---|---|---|---|---|
| Revenue | $196.60M | $177.80M | $160.80M | $154.60M |
| Net Income | -$31.20M | -$42.30M | -$7.60M | -$37.90M |
| EPS Diluted | — | — |
Myriad Genetics Inc · CIK 899923 · Engraved from SEC EDGAR
| — |
| -$0.50 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2023 · filed Feb 28, 2024 · 59 d after period end
